GlassScriptPhysician profile
Robert Huizenga
NPI 1245264720
$127,601.49
in general payments reported to CMS, 2019-2025
47 companies · $5,344 in 2025
The $5,344 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,019 · 2020: $743 · 2021: $1,301 · 2022: $24K · 2023: $76K · 2024: $19K · 2025: $5,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $80K · Travel and Lodging: $14K · Food and Beverage: $6,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $80,037.50 |
| Travel and Lodging | $13,612.98 |
| Food and Beverage | $6,682.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $121,345.37 | 2019-2025 | Repatha, Repatha, Otezla |
| Daiichi Sankyo INC. | $894.02 | 2019-2025 | Injectafer |
| Abbvie INC. | $888.57 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $590.34 | 2020-2025 | |
| Mannkind Corporation | $434.51 | 2019-2025 | Afrezza |
| Lilly USA, LLC | $360.32 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $263.94 | 2019-2024 | Xifaxan |
| Boston Scientific Corporation | $173.08 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $161.20 | 2019-2024 | Pifeltro, Delstrigo |
| Vistapharm, INC. | $145.08 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.18 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $119.16 | 2020-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $118.65 | 2019-2023 | Trintellix |
| Janssen Biotech, INC. | $118.24 | 2021-2022 | |
| Heartflow, INC. | $113.04 | 2022-2025 | Ffrct |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Huizenga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.